Lack of efficacy of ulinastatin therapy during cardiopulmonary bypass surgery

Chinese Medical Journal

Volumn 128, Issue 23, 2015, Pages 3138-3142

  Qiu, Yan ^a   Lin, Jing ^a   Yang, Yang ^b   Zhou, Jing ^a   Gong, Li Na ^a   Qin, Zhen ^a   Du, Lei ^a  

^a SICHUAN UNIVERSITY   (China)

^b GUIZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Cardiopulmonary bypass; Outcomes; Ulinastatin; Valves replacement

Indexed keywords

CREATININE; ULINASTATIN; GLYCOPROTEIN;

ACUTE KIDNEY FAILURE; ACUTE LUNG INJURY; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; CARDIOPULMONARY BYPASS; DEATH; DRUG EFFICACY; FEMALE; HEMODIALYSIS; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; SCORING SYSTEM; TRACHEOTOMY; ACUTE KIDNEY INJURY; ADVERSE EFFECTS; HEART SURGERY; LENGTH OF STAY; MIDDLE AGED; POSTOPERATIVE COMPLICATION; RESPIRATORY DISTRESS SYNDROME, ADULT;

ACUTE KIDNEY INJURY; ADULT; CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; FEMALE; GLYCOPROTEINS; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RESPIRATORY DISTRESS SYNDROME, ADULT; RETROSPECTIVE STUDIES;

EID: 84949024366     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.4103/0366-6999.170364     Document Type: Article

References (28)

1. Laffey JG, Boylan JF, Cheng DC. The systemic inflammatory response to cardiac surgery: Implications for the anesthesiologist. Anesthesiology 2002;97:215-52.
2. Hall RI, Smith MS, Rocker G. The systemic inflammatory response to cardiopulmonary bypass: Pathophysiological, therapeutic, and pharmacological considerations. Anesth Analg 1997;85:766-82.
3. Ng CS, Wan S. Limiting inflammatory response to cardiopulmonary bypass: Pharmaceutical strategies. Curr Opin Pharmacol 2012;12:155-9.
4. Warren OJ, Smith AJ, Alexiou C, Rogers PL, Jawad N, Vincent C, et al. The inflammatory response to cardiopulmonary bypass: Part 1 Mechanisms of pathogenesis. J Cardiothorac Vasc Anesth 2009;23:223-31.
5. Vohra HA, Whistance R, Modi A, Ohri SK. The inflammatory response to miniaturised extracorporeal circulation: A review of the literature. Mediators Inflamm 2009;2009:707-42.
6. Tang J, Tao K, Zhou J, Zhang C, Gong L, Luo N, et al. Long-t ermleukocyte filtration should be avoided during extracorporeal circulation. Mediators Inflamm 2013;2013:612-848.
7. Nakanishi K, Takeda S, Sakamoto A, Kitamura A. Effects of ulinastatin treatment on the cardiopulmonary bypass-induced hemodynamic instability and pulmonary dysfunction. Crit Care Med 2006;34:1351-7.
8. Xu CE, Zou CW, Zhang MY, Guo L. Effects of high-dose ulinastatin on inflammatory response and pulmonary function in patients with type-A aortic dissection after cardiopulmonary bypass unde rdeep hypothermic circulatory arrest. J Cardiothorac Vasc Anesth 2013;27:479-84.
9. Song J, Park J, Kim JY, Kim JD, Kang WS, Muhammad HB, et al.Effect of ulinastatin on perioperative organ function and systemic inflammatory reaction during cardiac surgery: A randomized double-blinded study. Korean J Anesthesiol 2013;64:334-40.
10. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, et al. The American-European Consensus Conference on ARDS Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994;149 (3 Pt 1):818-24.
11. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, et al. Acute kidney injury network: Report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007;11:R31.
12. Apostolakis E, Filos KS, Koletsis E, Dougenis D. Lung dysfunction following cardiopulmonary bypass. J Card Surg 2010;25:47-55.
13. Oh SY, Kim JC, Choi YS, Lee WK, Lee YK, Kwak YL. Effects of ulinastatin treatment on myocardial and renal injury in patients undergoing aortic valve replacement with cardiopulmonary bypass. Korean J Anesthesiol 2012;62:148-53.
14. Sandhaus RA, Turino G. Neutrophil elastase-mediated lung disease. COPD 2013;10 Suppl1:60-3.
15. Taggart DP, el-Fiky M, Carter R, Bowman A, Wheatley DJ. Respiratory dysfunction after uncomplicated cardiopulmonary bypass. Ann Thorac Surg 1993;56:1123-8.
16. Shin IW, Jang IS, Lee SM, Park KE, Ok SH, Sohn JT, et al. Myocardial protective effect by ulinastatin via an anti-inflammatory response after regional ischemia/reperfusion injury in an in vivo rat heart model. Korean J Anesthesiol 2011;61:499-505.
17. Aihara T, Shiraishi M, Hiroyasu S, Hatsuse K, Mochizuki H, Seki S ,et al. Ulinastatin, a protease inhibitor, attenuates hepatic isc hemia/reperfusion injury by downregulating TNF-alpha in the liver. Transplant Proc 1998;30:3732-4.
18. Nakahama H, Obata K, Sugita M. Ulinastatin ameliorates acute ischemic renal injury in rats. Ren Fail 1996;18:893-8.
19. Binns OA, DeLima NF, Buchanan SA, Mauney MC, Cope JT, Thies SD, et al. Neutrophil endopeptidase inhibitor improves pulmonary function during reperfusion after eighteen-hour preservation. J Thorac Cardiovasc Surg 1996;112:607-13.
20. Pasquali SK, Hall M, Li JS, Peterson ED, Jaggers J, Lodge AJ, et al. Corticosteroids and outcome in children undergoing congenital heart surgery: Analysis of the pediatric health information systems database. Circulation 2010;122:2123-30.
21. Dieleman JM, van Paassen J, van Dijk D, Arbous MS, K Alkman CJ, Vandenbroucke JP, et al. Prophylactic corticosteroids for cardiopulmonary bypass in adults. Cochrane Database Syst Rev 2011;11:CD005566.
22. Dieleman JM, Nierich AP, Rosseel PM, van der Maaten JM, Hofland J, Diephuis JC, et al. Intraoperative high-dose dexamethasone for cardiac surgery: A randomized controlled trial. JAMA 2012;308:1761-7.
23. Bunge JJ, van Osch D, Dieleman JM, Jacob KA, Kluin J, van Di jk D, et al. Dexamethasone for the prevention of postpericardiotomy syndrome: A dexamethasone for cardiac surgery substudy. Am Heart J 2014;168:126-31.e1.
24. He QL, Zhong F, Ye F, Wei M, Liu WF, Li MN, et al. Does intraoperative ulinastatin improve postoperative clinical outcomes in patients undergoing cardiac surgery: A meta-analysis of randomized controlled trials. Biomed Res Int 2014;2014:630-835.
25. Park JB, Kim SH, Lee SA, Chung JW, Kim JS, Chee HK. Effects of ulinastatin on postoperative blood loss and hemostasis in atrioventricular valve surgery with cardiopulmonary bypass. Korean J Thorac Cardiovasc Surg 2013;46:185-91.
26. Jönsson-Berling BM, Ohlsson K. Distribution and elimination of intravenously injected urinary trypsin inhibitor. Scand J Clin Lab Invest 1991;51:549-57.
27. Enzan K, Mitsuhata H, Masaki Y, Matsumoto J, Shigeomi S, Komatsu H, et al. Effects of ulinastatin on granulocyte elastase and fibronectin in patients undergoing cardiopulmonary bypass. Masui 1991;40:1625-31.
28. Cao Y, Yang T, Yu S, Sun G, Gu C, Yi D. Relationships of adiponectin with markers of systemic inflammation and insulin resistance in infants undergoing open cardiac surgery. Mediators Inflamm 2013;2013:187-940.